Journal article
Remdesivir for severe covid-19: a clinical practice guideline
Abstract
CLINICAL QUESTION: What is the role of remdesivir in the treatment of severe covid-19? This guideline was triggered by the ACTT-1 trial published in the New England Journal of Medicine on 22 May 2020.
CURRENT PRACTICE: Remdesivir has received worldwide attention as a potentially effective treatment for severe covid-19. After rapid market approval in the US, remdesivir is already being used in clinical practice.
Authors
Rochwerg B; Agarwal A; Zeng L; Leo Y-S; Appiah JA; Agoritsas T; Bartoszko J; Brignardello-Petersen R; Ergan B; Ge L
Journal
The BMJ, Vol. 370, ,
Publisher
BMJ
DOI
10.1136/bmj.m2924
ISSN
0959-8138
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
HumansAdenosine MonophosphateAlanineAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentGuideline AdherenceLength of StayNetwork Meta-Analysis as TopicPandemicsPneumonia, ViralRandomized Controlled Trials as TopicRespiration, ArtificialSARS-CoV-2Severity of Illness IndexTime FactorsTreatment OutcomeSystematic Reviews as Topic